Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lungcancer (NSCLC) patients: a systematic review and meta-analysis. Purpose: We designed the study to illustrate the OR of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor-related diarrhea in patients with non-small cell lungcancer. Method: This systematic review and meta-analysis were put into practice according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Incidence
tumors had significantly poorer OS (HR 1.69, 95% CI 1.21‒2.35, P=0.002), DFS (HR 1.27, 95% CI 1.07‒1.51, P=0.006) and RFS (HR 1.74, 95% CI 1.08‒2.80, P=0.020). In subgroup analyses, when the meta-analysis was limited to T1a-1b (≤2 cm) lungcancer, the prognosis for pure-solid tumors was inferior to that for part-solid tumors regarding both OS and RFS. In adenocarcinoma subgroup, there was no difference between the two groups in terms of OS and RFS, but we detected a meaningful difference in DFS (...) Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lungcancer in the eighth edition TNM classification. Objective: The aim of the study was to compare the prognoses between part-solid and pure-solid tumors for clinical stage IA non-small-cell lungcancer (NSCLC) patients in the eighth edition TNM classification. Methods: We searched the literature in PubMed and Web of Science for all eligible articles published before November 31, 2018
Human papillomavirus and lungcancer: an overview and a meta-analysis. This review is devoted to assessing the prevalence of human papillomavirus (HPV) in lungcancer (LC) in the world. HPV is recognized as the etiological factor of cervical cancer, however, there is widespread evidence that this virus is detected not only in gynecological carcinomas, but also in tumors of other organs, in particular the upper respiratory tract and digestive tract. A search was conducted to a depth of 29 years (...) in the PubMed, Web of Science, Scopus, databases. The review includes 95 articles.Of all the analyzed studies (9195 patients), 12 works showed a complete absence of HPV in the biological material in patients with LC. The absence of a virus among lungcancer patients has been established for Canada, the Netherlands and Singapore. The highest average percent of occurrence of this virus is shown for such countries as: Brazil, Korea, Greece and Taiwan (more than 40%). But the highest percentage of HPV
Clinicopathological and prognostic significance of Nanog expression in non-small cell lungcancer: a meta-analysis. Background: Nanog has been found to be overexpressed in various cancers. However, the association between Nanog expression and prognosis or clinicopathological features is still controversial. Therefore, this meta-analysis was conducted to identify whether Nanog expression was associated with prognosis or clinicopathological characteristics in non-small cell lungcancer (NSCLC (...) survival (OS) (HR=1.95, 95% CI: 1.38-2.75, P=0.000). Additionally, high Nanog expression was significantly correlated with tumor differentiation (OR=3.18, 95% CI: 1.69-5.98, P=0.000) and TNM stage (OR=1.78, 95% CI: 1.28-2.47, P=0.001). However, no significant relationship was observed between Nanog expression and other clinicopathological features, including gender (OR=0.95, 95% CI: 0.69-1.33, P=0.783), age (OR=0.78, 95% CI: 0.57-1.07, P=0.119), tumor size (OR=0.87, 95% CI: 0.26-2.95, P=0.824
The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lungcancer: a meta-analysis. Background: Extensive-disease small-cell lungcancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemotherapy for previously untreated ED-SCLC. While
The diagnostic accuracy of liquid exosomes for lungcancer detection: a meta-analysis. Several studies have suggested that liquid exosomes can be used as biomarkers for the diagnosis of lungcancer (LC). The purpose of this meta-analysis was to investigate the comprehensive diagnostic value of liquid exosomes for LC.Relevant studies were searched from multiple electronic databases. The quality of the studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2 criteria (...) ) of liquid exosomes in diagnosing LC were 0.82 (95% CI: 0.76-0.87), 0.84 (95% CI: 0.77-0.89), 5.27 (95% CI: 3.58-7.75), 0.21 (95% CI: 0.15-0.29), 25.14 (95% CI: 14.25-44.33), and 0.90 (95% CI: 0.87-0.92), respectively. Research based on serum, miRNA, the isolation kit method, one index in exosomes, patient sample size of 50 or greater, and control group size of 50 or greater obtained higher AUC values when the LC type was small cell lung cancer.Liquid exosomes have shown potential as novel biomarkers
Which Should Be Used First for ALK-Positive Non-Small-Cell LungCancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials. Background and objectives: Targeted therapy is widely used in the era of precision medicine. Whether the sequence in which targeted therapy and chemotherapy are performed matters, is however not known. We examined the impact of the sequential treatment of targeted therapy and chemotherapy among advanced anaplastic lymphoma kinase (ALK), non-small (...) cell lungcancer (NSCLC) patients. Materials and Methods: Randomized controlled trials comparing the use of ALK inhibitors with chemotherapy were included in this meta-analysis. We estimated the hazard ratios (HRs) and 95% confidence intervals (CI), for progression-free survival (PFS) and overall survival (OS) from a random effects model. Two-sided statistical tests were used to determine the significance of these estimates. Results: In five eligible studies (1404 patients), ALK targeted therapy
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lungcancer. To review and assess the quality of the available evidence on the cost-effectiveness of erlotinib in the first-line treatment of advanced non-small cell lungcancer (NSCLC).A systematic review was conducted to identify full-text original economic evaluations of erlotinib in the first-line treatment of advanced NSCLC written in English and published from the year
CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lungcancer: a systematic review and meta-analysis. To systematically analyze CT and clinical characteristics to find out the risk factors of epidermal growth factor receptor (EGFR) mutation in non-small cell lungcancer (NSCLC). Then the significant characteristics were used to set up a mathematic model to predict EGFR mutation in NSCLC.PubMed, Web of Knowledge and EMBASE up to August 17, 2018 were
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell LungCancer: A Systematic Review and Literature-Based Meta-Analysis. Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown superiority compared to chemotherapy alone as first-line therapy in advanced non-small cell lungcarcinoma (NSCLC). To evaluate the relative benefit in term of Overall Survival (OS) and Progression-free Survival (PFS
Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic LungCancer: A Systematic Review. Background: Immune checkpoint inhibitors (ICI) have represented a revolution in the treatment of non-small-cell lungcancer (NSCLC). To improve these results, combined approaches are being tested. The addition of stereotactic ablative radiotherapy (SABR) to ICI seems promising. A systematic review was performed
The Prognostic Value of Nanog Overexpression in LungCancer: A Meta-Analysis. Recent several studies have showed that the nanog overexpression leads to poor prognosis in some kinds of cancer including hepatocellular carcinoma and gastrointestinal luminal cancer. However, the correlations between prognosis and clinic-pathological features and nanog overexpression in lungcancer are still not well-known. Thus, we performed a meta-analysis to evaluate the role of nanog in lung cancer.An electronic (...) retrieval for related studies was conducted in PubMed, Cochrane Library, Web of Science, EMBASE databases, Chinese CNKI, and the Chinese Wan Fang database up to May 2018. The relationships between nanog overexpression and overall survival (OS) and disease-free survival (DFS) as well as clinic-pathological features in lungcancer were investigated. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by STATA12.11 studies containing 1422 patients were
Statin use and prognosis of lungcancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Previous clinical studies reported inconsistent results on the associations of statins with the mortality and survival of lungcancer patients. This review and meta-analysis summarized the impact of statins on mortality and survival of lungcancer patients.Eligible papers of this meta-analysis were searched by using PubMed, EMBASE, and Cochrane until July (...) mortality and promoted the overall survival of lungcancer patients. Statins showed an association with decreased all-cause mortality in cohort studies (HR =0.77, 95% CI: 0.59-0.99), but not in case-control studies (HR =0.75, 95% CI: 0.50-1.10). However, statin use showed no impact on mortality and overall survival in randomized controlled trials. Meanwhile, this meta-analysis indicated that statin use did not affect the progression-free survival of lungcancer patients in observational studies
VEGFR-TKIs combined with chemotherapy for advanced non-small cell lungcancer: A systematic review. Introduction: To estimate the efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in combination with chemotherapy for patients with advanced non-small cell lungcancer (NSCLC). Methods: We searched PubMed, PMC database, EMBASE, EBSCO-Medline, Cochrane Central Register of Controlled Trials (CENTRAL), American Society of Clinical Oncology (...) (ASCO), International Association for the Study of LungCancer (IASLC) and the European Society of Medical Oncology (ESMO), http://www.clinicaltrials.gov/, CNKI, and Wanfang databases to identify primary research reporting the survival outcomes and safety of VEGFR-TKIs in patients with advanced NSCLC. A meta-analysis was conducted to generate combined hazard ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS), progression-free survival (PFS), objective response rate (ORR
The Impact of Afatinib on Survival in Advanced Non-Small Cell LungCancer: A Meta-Analysis of Randomized Controlled Trials. Background: Afatinib is a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been approved by the Food and Drug Administration for the treatment of advanced non-small cell lungcancer (NSCLC) harboring EGFR mutations. We performed a meta-analysis to assess the efficacy and safety of afatinib in advanced NSCLC. Methods: We
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lungcancer: a network meta-analysis. EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lungcancer (NSCLC) harboring EGFR mutations. However, an overall view for comparing efficacy and toxicity on a meta-level is lacking. This study compared efficacy
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lungcancer: A meta-analysis of randomized clinical trials. This meta-analysis systematically evaluated the efficacy of PD-1 and PD-L1 inhibitors for the treatment of advanced non-small cell lungcancer (NSCLC) and investigated the efficacy of first-line therapy and PD-1 versus PD-L1 inhibitors.PubMed, The Cochrane Library, and Embase were searched up to November 2018 for randomized controlled trials (RCTs) for eligible (...) The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lungcancer: a meta-analysis of literatures. Epidermal growth factor receptor (EGFR) mutation represents a good response to EGFR-tyrosine kinase inhibitor and an advantageous prognostic factor in advanced-stage non-small cell lungcancer (NSCLC). However, the predictive value of EGFR mutation for prognosis in NSCLC patients after complete surgery, which more reflective of natural process (...) , remains controversial. We sought to examine the predictive value of EGFR mutation in NSCLC. Several studies with small sample sizes have been reported but small studies bring bias especially in a postoperative setting. Therefore, we sought to pool all current evidence to show the true effects.Electronic databases were used to search the relevant articles. Disease-free survival (DFS), which will be less effected by subsequent treatments after recurrence, was the primary endpoint. The DFS between EGFR
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell LungCancer: A Meta-analysis and Individual Patient-Level Analysis. The beneficial role of immunotherapy and the clinical relevance of current biomarkers in non-small cell lungcancer (NSCLC) remain inconclusive; thus, appropriate strategies and reliable predictors need further definition.To evaluate the association of clinical outcomes with immune checkpoint inhibitors, tumor vaccines (...) -small cell lungcarcinoma. Systematic reviews, meta-analyses, references, and conference proceedings were manually searched.English-language randomized clinical trials with available data that measured overall survival (OS), progression-free survival (PFS), or objective response rate comparing immune checkpoint inhibitors, tumor vaccines, or cellular immunotherapy with conventional therapy for patients with advanced or metastatic NSCLC were included. Thirty-one immunotherapy randomized clinical